Kerstin Kempf1, Bernd Altpeter2, Janine Berger2, Oliver Reuß3, Matthias Fuchs3, Michael Schneider4,5, Babette Gärtner6, Katja Niedermeier6, Stephan Martin6,7. 1. West-German Centre of Diabetes and Health, Düsseldorf Catholic Hospital Group, Düsseldorf, Germany kerstin.kempf@wdgz.de. 2. German Institute for Telemedicine and Healthpromotion, Düsseldorf, Germany. 3. Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany. 4. Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany. 5. Mannheim Institute for Public Health, Medical Faculty Mannheim, Ruprecht-Karls University Heidelberg, Mannheim, Germany. 6. West-German Centre of Diabetes and Health, Düsseldorf Catholic Hospital Group, Düsseldorf, Germany. 7. Faculty of Medicine, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Abstract
OBJECTIVE:Lifestyle interventions are the foundation of treatment in newly diagnosed type 2 diabetes. However, their therapeutic potential in advanced disease stages is unknown. We evaluated the efficacy of the Telemedical Lifestyle intervention Program (TeLiPro) in improving metabolic control in advanced-stage type 2 diabetes. RESEARCH DESIGN AND METHODS: In this single-blind, active comparator, intervention study, patients with type 2 diabetes (with glycated hemoglobin [HbA1c] ≥7.5% [58.5 mmol/mol]), and BMI ≥27 kg/m2 and on ≥2 antidiabetes medications) were recruited in Germany and randomized 1:1 using an electronically generated random list and sealed envelopes into two parallel groups. The data analyst was blinded after assignment. The control group (n = 100) got weighing scales and step counters and remained in routine care. The TeLiPro group (n = 102) additionally received telemedical coaching including medical-mental motivation, a formula diet, and self-monitored blood glucose for 12 weeks. The primary end point was the estimated treatment difference in HbA1c reduction after 12 weeks. All available values per patient (n = 202) were analyzed. Analyses were also performed at 26 and 52 weeks of follow-up. RESULTS:HbA1c reduction was significantly higher in the TeLiPro group (mean ± SD -1.1 ± 1.2% vs. -0.2 ± 0.8%; P < 0.0001). The estimated treatment difference in the fully adjusted model was 0.8% (95% CI 1.1; 0.5) (P < 0.0001). Treatment superiority of TeLiPro was maintained during follow-up (week 26: 0.6% [95% CI 1.0; 0.3], P = 0.0001; week 52: 0.6% [0.9; 0.2], P < 0.001). The same applies for secondary outcomes: weight (TeLiPro -6.2 ± 4.6 kg vs. control -1.0 ± 3.4 kg), BMI (-2.1 ± 1.5 kg/m2 vs. -0.3 ± 1.1 kg/m2), systolic blood pressure (-5.7 ± 15.3 mmHg vs. -1.6 ± 13.8 mmHg), 10-year cardiovascular disease risk, antidiabetes medication, and quality of life and eating behavior (P < 0.01 for all). The effects were maintained long-term. No adverse events were reported. CONCLUSIONS: In advanced-stage type 2 diabetes, TeLiPro can improve glycemic control and may offer new options to avoid pharmacological intensification.
RCT Entities:
OBJECTIVE: Lifestyle interventions are the foundation of treatment in newly diagnosed type 2 diabetes. However, their therapeutic potential in advanced disease stages is unknown. We evaluated the efficacy of the Telemedical Lifestyle intervention Program (TeLiPro) in improving metabolic control in advanced-stage type 2 diabetes. RESEARCH DESIGN AND METHODS: In this single-blind, active comparator, intervention study, patients with type 2 diabetes (with glycated hemoglobin [HbA1c] ≥7.5% [58.5 mmol/mol]), and BMI ≥27 kg/m2 and on ≥2 antidiabetes medications) were recruited in Germany and randomized 1:1 using an electronically generated random list and sealed envelopes into two parallel groups. The data analyst was blinded after assignment. The control group (n = 100) got weighing scales and step counters and remained in routine care. The TeLiPro group (n = 102) additionally received telemedical coaching including medical-mental motivation, a formula diet, and self-monitored blood glucose for 12 weeks. The primary end point was the estimated treatment difference in HbA1c reduction after 12 weeks. All available values per patient (n = 202) were analyzed. Analyses were also performed at 26 and 52 weeks of follow-up. RESULTS: HbA1c reduction was significantly higher in the TeLiPro group (mean ± SD -1.1 ± 1.2% vs. -0.2 ± 0.8%; P < 0.0001). The estimated treatment difference in the fully adjusted model was 0.8% (95% CI 1.1; 0.5) (P < 0.0001). Treatment superiority of TeLiPro was maintained during follow-up (week 26: 0.6% [95% CI 1.0; 0.3], P = 0.0001; week 52: 0.6% [0.9; 0.2], P < 0.001). The same applies for secondary outcomes: weight (TeLiPro -6.2 ± 4.6 kg vs. control -1.0 ± 3.4 kg), BMI (-2.1 ± 1.5 kg/m2 vs. -0.3 ± 1.1 kg/m2), systolic blood pressure (-5.7 ± 15.3 mmHg vs. -1.6 ± 13.8 mmHg), 10-year cardiovascular disease risk, antidiabetes medication, and quality of life and eating behavior (P < 0.01 for all). The effects were maintained long-term. No adverse events were reported. CONCLUSIONS: In advanced-stage type 2 diabetes, TeLiPro can improve glycemic control and may offer new options to avoid pharmacological intensification.
Authors: Anastasia-Stefania Alexopoulos; William S Yancy; David Edelman; Cynthia J Coffman; Amy S Jeffreys; Matthew L Maciejewski; Corrine I Voils; Nicole Sagalla; Anna Barton Bradley; Moahad Dar; Stéphanie B Mayer; Matthew J Crowley Journal: Chronic Illn Date: 2019-10-25
Authors: Kerstin Kempf; Martin Röhling; Winfried Banzer; Klaus Michael Braumann; Martin Halle; David McCarthy; Hans Georg Predel; Isabelle Schenkenberger; Susanne Tan; Hermann Toplak; Aloys Berg; Stephan Martin Journal: Nutrients Date: 2021-04-23 Impact factor: 5.717
Authors: Kerstin Kempf; Martin Röhling; Monika Stichert; Gabriele Fischer; Elke Boschem; Jürgen Könner; Stephan Martin Journal: Int J Telemed Appl Date: 2018-09-09
Authors: David Koot; Paul Soo Chye Goh; Robyn Su May Lim; Yubing Tian; Teng Yan Yau; Ngiap Chuan Tan; Eric Andrew Finkelstein Journal: JMIR Mhealth Uhealth Date: 2019-05-24 Impact factor: 4.773
Authors: Yilin Yoshida; Suzanne A Boren; Jesus Soares; Mihail Popescu; Stephen D Nielson; Eduardo J Simoes Journal: Curr Diab Rep Date: 2018-10-18 Impact factor: 4.810
Authors: Kiersten L Strombotne; Jessica Lum; Nambi J Ndugga; Anne E Utech; Steven D Pizer; Austin B Frakt; Paul R Conlin Journal: Diabetes Obes Metab Date: 2021-08-19 Impact factor: 6.577